Doravirine versus Darunavir
Doravirine is an experimental non-nuke that is undergoing phase III clinical trials. It is designed to be effective against most strains of HIV that are resistant to other non-nukes, such as the following:
Doravirine can be dosed once daily with or without food. In addition to being developed in a 100-mg pill, doravirine is also being developed as a fixed-dose formulation with the following two drugs:
Merck, the developer of doravirine, recently conducted a randomized, placebo-controlled study comparing regimens based on doravirine to regimens based on darunavir (Prezista and Prezcobix). Darunavir is the leading protease inhibitor used in high-income countries today. It has to be taken with a small dose of another drug, ritonavir (Norvir), which helps to boost or maintain levels of darunavir in the blood so that it can be taken only once daily. In its clinical trial Merck found that doravirine was roughly equivalent in potency to darunavir-based regimens.
Upon entering the study the average profile of participants was as follows:
The nukes used in this study were as follows:
Data were released on study participants after one year. Their distribution was as follows:
The study will continue for two years.
Results -- Changes in Viral Load and CD4+ Cell Counts
Overall, after one year, the proportions of participants who had a viral load less than 50 copies/mL were distributed as follows:
Statistical analysis found that both regimens are roughly equivalent (the technical term for this is non-inferior).
The following proportions of participants were unable to keep their viral load suppressed:
Data from the remaining participants was not yet available.
Among participants who entered the study with a viral load greater than 100,000 copies/mL, the proportions with a suppressed viral load at week 48 were as follows:
Among participants who entered the study with a CD4+ count greater than 200 cells/mm3, the proportions that were virologically suppressed at week 48 were as follows:
Among participants who entered the study with a CD4+ count between 51 and 200 cells/mm3, the proportions with a suppressed viral load at week 48 were as follows:
Among participants who entered the study with a CD4+ count of 50 or less cells/mm3, the proportions with a suppressed viral load at week 48 were as follows:
CD4+ cell counts increased over the course of the study. Below are the average increases in e cell counts for each regimen by week 48:
This difference in CD4+ cell counts was not statistically significant.
About 30% of all participants experienced side effects; this is relatively common when people begin HIV treatment in or out of clinical trials. In most cases, side effects should fade after a few weeks. However, 2% of participants on doravirine and 3% on darunavir had to quit the study due to side effects.
Common side effects were distributed as follows:
This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication TreatmentUpdate. Visit CATIE's Web site to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.